56 results about "Meningitides" patented technology

The composition is prepared from group B meningococcus NHBA recombinant protein, fHbp (V1-V1) recombinant protein and fHbp (V2-V3) recombinant protein obtained through artificial modification, or three corresponding recombinant proteins obtained by further adding P4 signal peptide on the basis of the group B meningococcus NHBA recombinant protein, the fHbp (V1-V1) recombinant protein and the fHbp (V2-V3) recombinant protein, and animal experiments prove that the composition has good immunogenicity and can be used for preparing the immunopotentiator. The compound can be used for preparing vaccines for preventing group B meningococcus.

Provided are protein nanostructures that display Neisseria meningitidis factor H binding protein (fHBP). The protein nanostructure may be a two-component icosahedral nanostructure. Further provided are vaccine compositions, methods of manufacturing, and methods of use, e.g., immunizing a subject to generate a protective immune response to Neisseria meningitidis.

Aspects of the disclosure relate to compositions and methods for base editing using viral vectors. In some aspects, the disclosure provides an adenine base editor (ABE) utilizing an evolved Cas9 nickase derived from Neisseria meningitidis; and adeno-associated viruses (AAVs) comprising (or encoding) such adenine base editors. In some aspects, compositions described herein are useful for treatment of certain diseases, for example pulmonary diseases.

In one aspect, the disclosure relates to a composition including a factor H binding protein (fHBP) and a Neisseria meningitidis non-serogroup B capsular polysaccharide, and methods of use thereof. The disclosure further relates to uses of a composition that includes fHBP, such as, for example, uses to elicit an immune response against N. meningitidis serogroup B strains and non-serogroup B strains. The compositions and methods described herein are directed to administration in humans, including adults, adolescents, toddlers, and infants.

The present invention provides fusion proteins having the desire to reduce Factor H binding, in particular the present invention provides optimized processes for the manufacture of fusion proteins and formulations comprising fusion proteins. The present invention provides an effective platform process for the manufacture of an effective vaccine formulation against Neisseria meningitidis, which meets a variety of criteria, including improved immunogenicity, safety, stability, and burdenability.

The present application provides a kind of protecting group B meningococcal infection outer membrane vesicle composition, the outer membrane vesicle composition is by lipopolysaccharide modified group B meningococcal outer membrane vesicle and the outer membrane vesicle of group B meningococcal bacterium expressing recombinant protein is composed.The outer membrane vesicle composition provided by the present application has better protective effect on group B meningococcal infection relative to single strain outer membrane vesicle, and is more suitable for use as vaccine.

The invention relates to biological pharmacy. In particular, the present invention relates to a mutant factor H binding protein (fHbp) of Neisseria meningitidis serogroup B. In addition, the present invention relates to a composition for the prevention of the Factor H binding protein (fHbp) of Neisseria meningitidis. In particular, the present invention relates to mutant factor H binding proteins (fHbp) of Neisseria meningitidis, compositions thereof, and uses thereof. The invention also relates to the use of said mutant factor H binding protein (fHbp) in the treatment or prevention or diagnosis of neisseria meningitidis disease caused by at least one of serogroup A, C, B, Y and W diseases. In particular, the invention relates to a pharmaceutical composition comprising said mutant Factor H binding protein (fHbp) for use in the treatment or prevention or diagnosis of Neisseria meningitidis serogroup B disease.

The present disclosure is drawn to an endolysin protein against Streptococcus pneumoniae (Spn), designated SP-CHAP. The disclosure provides methods of treating diseases in a subject resulting from infection with pneumococcal bacteria, said diseases including but not limited to pneumonia, invasive pneumococcal disease, meningitis and sepsis. Such treatment methods include administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising SP-CHAP polypeptide, polypeptide fragments, SP-CHAP encoding nucleic acids (RNA / DNA) or variants thereof.

This invention relates, inter alia, to an immunogenic fragment of a Neisserial Heparin Binding Antigen (NHBA) protein of Neisseria gonorrhoeae (SEQ ID NO: 1) for the prevention and treatment of Neisseria gonorrhoeae or gonococcal- or meningococcal-associated diseases and conditions. In some embodiments, the immunogenic fragment corresponds to a C-terminal fragment of the protein (SEQ ID NO: 2).

Meningococcal vaccines can be improved by including multiple alleles or variants of fHbp, in order to provide broader coverage of the diversity which is known for this protein, and / or by reducing the quantity of an OMV component in each dose.

The present invention relates to a multiplex gene detection system for viral and bacterial infection of the central nervous system, comprising forward and reverse primers for detecting enterovirus, human double echovirus, Mycobacterium tuberculosis, Listeria monocytogenes, Streptococcus pneumoniae, varicella zoster virus, mumps virus, cytomegalovirus, herpes simplex virus type 1, herpes simplex virus type 2, Neisseria meningitidis, Epstein-Barr virus, Streptococcus agalactiae, Haemophilus influenzae, human herpes virus type 6, Escherichia coli K1 and Japanese encephalitis virus, and the detection sample is cerebrospinal fluid. The multiplex gene detection product for viral and bacterial infection of the central nervous system of the present invention has high throughput, low cost, high sensitivity and good specificity, and is used for synchronous identification and semi-quantitative analysis of multiple viral and bacterial infections of the central nervous system.

The present invention relates to an immunogenic composition against Neisseria meningitidis serogroup B in liquid form and a reconstituted vaccine against Neisseria meningitidis serogroups A, B, C, W135, and Y comprising this liquid composition. Also provided are kits and methods for the prevention and treatment of Neisseria meningitidis infections and diseases using the immunogenic composition or the reconstituted vaccine.

The present invention relates to compositions and methods for preventing and / or treating bacterial disease (e.g., disease caused by Neisseria spp. such as Neisseria gonorrhoeae or Neisseria meningitidis). In particular, the present invention provides compositions comprising an effective amount of a nucleic acid, wherein such compositions are capable of killing or inhibiting the growth of a Neisseria spp and sensitizing Neisseria spp to antibiotic treatment.

The present invention relates to the field of protein engineering modification. Provided are a group B neisseria meningitides antigen fusion protein combination and the use thereof. The antigen fusion protein combination comprises an antigen fusion protein, the antigen fusion protein comprising two or more antigens or fragments thereof that are optionally selected from the following: (i) an fHbp antigen; (ii) an NHBA antigen; (iii) an NadA antigen; or (iv) a PorA loop. The designed antigen fusion protein can combine one or more different subtypes for administration, thereby producing more broad-spectrum immune effects, improving the stability of the antigens, simplifying the production process and reducing costs.

The present invention provides a fusion protein in which H factor binding is desiredly reduced, and in particular, the present invention provides an optimized manufacturing process for the fusion protein and formulations containing the fusion protein. The present invention provides an efficient platform process for producing effective vaccine formulations against Neisseria meningitidis that meet multiple criteria with improved immunogenicity, safety, stability and availability.

The invention discloses issatchenkia orientalis capable of efficiently synthesizing L-malic acid and application of the issatchenkia orientalis, and belongs to the technical field of biological engineering. In an existing gene edited yeast strain in a laboratory, endogenous lactic dehydrogenase IoLDH2 and IoLDH3 are over-expressed, endogenous IoLDH1 is knocked out, and lactic dehydrogenase EcD-LDH from escherichia coli and lactic dehydrogenase NmD-LDH from neisseria meningitidis are over-expressed. After fermentation for 72 h in a 5 L fermentation tank, the accumulation amount of L-malic acid reaches 296.27 g / L, the yield is 0.97 g / g, the production intensity is 4.11 g / L / h, and the by-product lactic acid is remarkably reduced from 23.56 g / L to 6.7 g / L and is reduced by 71.56%.

The invention relates to a pentavalent neisseria meningitidis capsular polysaccharide protein conjugate vaccine. The neisseria meningitidis capsular polysaccharide protein conjugate comprises a group A neisseria meningitidis capsular polysaccharide protein conjugate, a group C neisseria meningitidis capsular polysaccharide protein conjugate, a group Y neisseria meningitidis capsular polysaccharide protein conjugate, a group W135 neisseria meningitidis capsular polysaccharide protein conjugate and a group X neisseria meningitidis capsular polysaccharide protein conjugate. According to the neisseria meningitidis pentavalent vaccine provided by the invention, on the basis of an ACYW135 neisseria meningitidis tetravalent polysaccharide conjugate vaccine, the protection range is expanded, the vaccination times of infants, teenagers and adults are reduced, and the vaccination cost is reduced.

This application relates to the technical field of biomedicine, and particularly to a meningococcal outer membrane protein synthetic peptide and its application. This application discloses a meningococcal outer membrane protein synthetic peptide and its application. The amino acid sequence of the polypeptide is at least one of (I) to (IV): (I) the amino acid sequence shown in SEQ ID NO.1; (II) the amino acid sequence shown in SEQ ID NO.2; (III) the amino acid sequence shown in SEQ ID NO.3; (IV) the amino acid sequence shown in SEQ ID NO.4. This application discloses a meningococcal outer membrane protein synthetic peptide and its application, and discloses the polypeptide sequence. The vaccine made from this polypeptide or its polymer can effectively cope with the antigen diversity of meningococcal PorA and PorB, is easy to synthesize on a large scale, and has good application prospects.

The invention relates to the field of protein engineering. The invention provides a group B meningococcus antigen fusion protein composition and application thereof, the group B meningococcus antigen fusion protein composition comprises an antigen fusion protein, and the antigen fusion protein comprises two or more than two antigens or fragments thereof optionally selected from the following antigens: (i) an fHbp antigen; (ii) an NHBA antigen; (iii) a NadA antigen; or (iv) a PorA loop region (loop). The designed antigen fusion protein can be applied in combination with one or more different subtypes, a broader-spectrum immune effect is generated, meanwhile, the stability of the antigen is improved, the production process is simplified, and the production cost is reduced.

The present disclosure provides nanostructures and nanostructure-based vaccines. Some nanostructures of the present disclosure display antigens capable of eliciting an immune response to infectious agents such as bacteria, viruses, and pathogens. Some vaccines of the present disclosure are useful for preventing or reducing the severity of infection by infectious agents including, but not limited to, Lyme disease, pertussis, herpes virus, orthomyxovirus, paramyxovirus, pneumovirus, filovirus, flavivirus, reovirus, retrovirus, meningococcus, or malaria. The antigens can be attached to the core of the nanostructure non-covalently or covalently, including as a fusion protein or by other means disclosed herein. Multimeric antigens can optionally be displayed along the symmetry axis of the nanostructure. Also provided are proteins and nucleic acid molecules encoding such proteins, vaccine compositions, and methods of administration.

The present invention discloses the application of oral microbiota in the diagnosis of heart failure. The present invention has for the first time discovered a combination of biomarkers related to the diagnosis of heart failure, namely Streptococcus, Neisseria, Neisseria subflava, Veillonella parvula, Neisseria cinerea, Haemophilus parainfluenzae, Neisseria meningitidis, Geotrichum candidum, Haemophilus influenzae, and Veillonella massiliensis. By detecting the abundances of the biomarkers in the oral microbiota of a subject, heart failure can be diagnosed, thereby better intervening in the occurrence and development of heart failure and guiding clinicians to provide prevention or treatment plans for the subject.

Provided are protein nanostructures that display Neisseria meningitidis factor H binding protein (fHBP). The protein nanostructure may be a two-component icosahedral nanostructure. Further provided are vaccine compositions, methods of manufacturing, and methods of use, e.g., immunizing a subject to generate a protective immune response to Neisseria meningitidis.

Tetracoordinate organoborate compounds, such as compounds harboring a tetraarylborate anion or a triarylalkylborate anion, are shown to exhibit a selective bacteriostatic and bactericidal effect against pathogenic Neisseria species such as N. meningitidis N and N. gonorrhoeae. Exemplified active compounds include the tetraphenylborate anion (BPh4-) and a cyclic zwitterionic borinic acid ethanolamine ester. The use of such borate compounds for the treatment of pathogenic Neisseria infections is also described.

The present inventors have identified a combination vaccine for immunization against bacterial meningitis caused by multiple pathogens.

The present disclosure relates to monoclonal antibodies targeting a Neisseria meningitidis serogroup B (MenB) antigen and their use for in vitro assay of the potency of MenB antigen for the manufacture of vaccine for preventing meningococcal infection.

The present invention is related to compositions and methods for gene therapy. Several approaches described herein utilize the Neisseria meningitidis Cas9 system that provides a hyperaccurate CRISPR gene editing platform. Furthermore, the invention incorporates full length and truncated single guide RNA sequences that permit a complete sgRNA-Nme1Cas9 vector to be inserted into an adeno-associated viral plasmid that is compatible for in vivo administration. Furthermore, Type II-C Cas9 orthologs have been identified that target protospacer adjacent motif sequences limited to between one-four required nucleotides.

The invention relates to a sexavalent neisseria meningitidis combination vaccine composition. The sexavalent neisseria meningitidis combination vaccine composition comprises a group A neisseria meningitidis capsular polysaccharide, a group C neisseria meningitidis capsular polysaccharide, a group Y neisseria meningitidis capsular polysaccharide, a group W135 neisseria meningitidis capsular polysaccharide, a group X neisseria meningitidis capsular polysaccharide and a group B neisseria meningitidis human factor H binding protein (fHbp). The invention further relates to a preparation method and application of the sexavalent neisseria meningitidis combined vaccine composition in different dosage forms, the immune coverage rate is increased, and the protection range of neisseria meningitidis infection is widened.

The application belongs to the field of genetic engineering and enzyme engineering, and discloses a kind of N-acetylneuraminic acid synthase mutant and its application in N-acetylneuraminic acid production, the mutant NeuB C86T is obtained by site-specific mutation on wild-type N-acetylneuraminic acid synthase from Neisseria meningitidis (N. meningitidis) Neisseria meningitidis The 86th amino acid is replaced from cysteine (C) to threonine (T). Through high performance liquid chromatography (HPLC) analysis of N-acetylneuraminic acid yield, the results show that, compared with wild-type enzyme, the mutant NeuB C86T The synthesis efficiency of N-acetylneuraminic acid is significantly improved by 57%, which indicates that it has potential superiority in producing N-acetylneuraminic acid.

To provide a compound of formula (I) as described herein, pharmaceutically acceptable salts, pharmaceutical compositions containing such compounds, and methods for using these compounds, salts, and compositions to treat viral infections. [Solution] The present invention relates to a novel 1,3-dioxoindene compound that is an inhibitor of picornaviruses, including coxsackievirus, enterovirus, echovirus, poliovirus, and rhinovirus, and is therefore useful for treating viral infections, including polio, paralysis, acute hemorrhagic conjunctivitis, viral meningitis, hand-foot-and-mouth disease, vesicular diseases, hepatitis A, myositis, myocarditis, pancreatitis, diabetes mellitus, epidemic myalgia, encephalitis, common cold, herpangina, foot-and-mouth disease, asthma, chronic obstructive pulmonary disease, pneumonia, sinusitis, or otitis media.

The disclosure relates to an immunogenic composition comprising a combination of Neisseria meningitidis serogroup B antigens, said combination comprising at least one factor H binding protein (fHBP) A and at least one factor H binding protein (fHBP) B, and an aluminum hydroxyphosphate (AlPO4) adjuvant, the AlPO4 adjuvant being selected as having a point of zero charge (PZC) below 5.